Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1819-1828

  Wu, Xiaoping ^a,b   Huang, Huixian ^b   Wang, Cong ^a,b   Lin, Shaoqiang ^a   Huang, Yadong ^b   Wang, Yi ^a   Liang, Guang ^a   Yan, Qiuxia ^b   Xiao, Jian ^a   Wu, Jianzhang ^a   Yang, Yongguang ^c   Li, Xiaokun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

bFGF; Cancer therapy; Phage display; Proliferation

Indexed keywords

ARGININE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; COAT PROTEIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPTAPEPTIDE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROLINE; SERINE; SYNTHETIC PEPTIDE; TYROSINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOPANNING; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STRAIN 3T3; CELL STRAIN COS7; CONTROLLED STUDY; DNA SEQUENCE; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING;

3T3 CELLS; ANIMALS; CELL GROWTH PROCESSES; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING;

EID: 84886737575     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1312     Document Type: Article

References (29)

1. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug. Discov. 2009; 8: 235-253.
2. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr. Cancer Drug Targets. 2009; 9: 639-651.
3. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr. Pharm. Des. 2007; 13: 2025-2044.
4. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur. Urol. 2003; 43: 309-319.
5. Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, Zeng Y, Wang Y, Nie C, Yang Y, Li X. Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J. Cell. Mol. Med. 2010; 14: 351-356.
6. Tsunoda S, Nakamura T, Sakurai H, Saiki I. Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci. 2007; 98: 541-548.
7. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, Roncali L, Dammacco F. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer. 2003; 39: 666-674.
8. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 246-250.
9. Igarashi M, Finch PW, Aaronson SA. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J. Biol. Chem. 1998; 273: 13230-13235.
10. Maruta F, Parker AL, Fisher KD, Hallissey MT, Ismail T, Rowlands DC, Chandler LA, Kerr DJ, Seymour LW. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther. 2002; 9: 543-552.
11. Johnston CL, Cox HC, Gomm JJ, Coombes RC. bFGF and aFGF induce membrane ruffling in breast cancer cells but not in normal breast epithelial cells: FGFR-4 involvement. Biochem. J. 1995; 306 ( Pt 2): 609-616.
12. Ying W, Martineau D, Beitz J, Lappi DA, Baird A. Anti-B16-F10 melanoma activity of a basic fibroblast growth factor-saporin mitotoxin. Cancer. 1994; 74: 848-853.
13. Beitz JG, Davol P, Clark JW, Kato J, Medina M, Frackelton Jr AR, Lappi DA, Baird A, Calabresi P. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer Res. 1992; 52: 227-230.
14. Kandel E. Tumor-associated oncogenes go on (phage) display. Oncotarget. 2010; 1: 84-85.
15. Ionov Y. A high throughput method for identifying personalized tumor-associated antigens. Oncotarget. 2010; 1: 148-155.
16. Ferrieu-Weisbuch C, Michel S, Collomb-Clerc E, Pothion C, Deléage G, Jolivet-Reynaud C. Characterization of prostate-specific antigen binding peptides selected by phage display technology. J. Mol. Recognit. 2006; 19: 10-20.
17. Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol. Ther. 2010; 125: 105-117.
18. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer. 2003; 104: 527-532.
19. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, McBrian M, Gupta AR, Eck SL, Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene. 1999; 18: 6469-6476.
20. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 2000; 12: 547-554.
21. Lefevre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Invest. Ophthalmol. Vis. Sci. 2009; 50: 1047-1057.
22. Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994; 79: 551-555.
23. Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 2001; 3: 950-957.
24. Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouysségur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 8319-8323.
25. Bae DG, Kim TD, Li G, Yoon WH, Chae CB. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin. Cancer Res. 2005; 11: 2651-2661.
26. Xu Y, Zhao H, Zheng Y, Gu Q, Ma J, Xu X. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Mol. Vis. 2010; 16: 1982-1995.
27. Liu S, Edwards DS. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chem. Rev. 1999; 99: 2235-2268.
28. Posch C, Ortiz-Urda S. NRAS mutant melanoma--undrugable? Oncotarget. 2013; 4: 494-495.
29. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999; 59: 4919-4926.